Last reviewed · How we verify
Ovarian Stimulation with rFSH
Recombinant follicle-stimulating hormone (rFSH) stimulates the growth and maturation of ovarian follicles to produce multiple eggs for assisted reproductive procedures.
Recombinant follicle-stimulating hormone (rFSH) stimulates the growth and maturation of ovarian follicles to produce multiple eggs for assisted reproductive procedures. Used for Ovarian stimulation for assisted reproductive technology (ART) including in vitro fertilization (IVF), Ovulation induction in anovulatory women.
At a glance
| Generic name | Ovarian Stimulation with rFSH |
|---|---|
| Sponsor | Fundación Santiago Dexeus Font |
| Drug class | Gonadotropin |
| Target | FSH receptor (FSHR) |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | FDA-approved |
Mechanism of action
rFSH is a recombinant gonadotropin that binds to FSH receptors on granulosa cells in the ovary, promoting follicle development and estrogen production. This controlled ovarian hyperstimulation allows retrieval of multiple mature oocytes for in vitro fertilization or other fertility treatments. The dose and duration are carefully titrated to achieve optimal follicle development while minimizing ovarian hyperstimulation syndrome risk.
Approved indications
- Ovarian stimulation for assisted reproductive technology (ART) including in vitro fertilization (IVF)
- Ovulation induction in anovulatory women
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Headache
- Injection site reactions
- Abdominal pain/bloating
- Nausea
- Mild fever
Key clinical trials
- INTEnsity of ovariaN Stimulation and Embryo Quality (PHASE4)
- rFSH vs rFSH+rLH in Dydrogesterone-Based Progestin Protocol: A Prospective Study
- Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization. (PHASE4)
- hCG Priming in Women With Diminished Ovarian Reserve (PHASE3)
- Usefulness of Corifollitropin α as Alternative to Conventional Daily rFSH Protocols in Oocyte Donors Undergoing Pituitary Suppression With Medroxiprogesterona Acetate (MPA) (NA)
- Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment (NA)
- Does Recombinant FSH (rFSH, i.g. Gonal F®) as Compared to Human Menopausal Gonadotrophin (hMG) Affect Telomere Length of Cumulus Cells During Antral Follicle Growth and Impact Blastocyst Status?
- Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Indian Women (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ovarian Stimulation with rFSH CI brief — competitive landscape report
- Ovarian Stimulation with rFSH updates RSS · CI watch RSS
- Fundación Santiago Dexeus Font portfolio CI